ADx logo

Expertise & Technology

Pharma solutions

Many people suffer from dementia and other neurodegenerative conditions, and the number of patients keeps increasing. Unfortunately, little therapy is available for patients suffering from dementia or Alzheimer’s disease.

The pharmaceutical industry is actively searching for improved therapies to help these patients. However, testing these new therapies in large clinical trials is very demanding. Pharmaceutical companies can rely on the ADx antibodies and services to accelerate and improve the design of clinical trials. The ADx technology allows to screen, identify and diagnose patients on a large scale and enrollment in relevant clinical trials.

 

"We rely on the ADx-biomarkers for diagnosis and identification of patients eligible for clinical trials. They deliver robust and reliable results. Early diagnosis is key to accelerate the search for an effective therapy." 
- Prof. Dr. Sebastiaan Engelborghs, neuroscientist at the University of Antwerp, Belgium

ADx helps pharmaceutical companies to forward therapeutic candidates from pre-clinical studies into clinical trials with its biomarkers. ADx collaborates with pharmaceutical companies on a global scale. A first step in such a collaboration is to provide pre-clinical trial sample testing service (animal + human), especially with these biomarkers for which no robust test kits are available yet. Later on, test kits are manufactured on a large scale in order to be used in the clinical trials.